Fecal marker variability in colorectal cancer: Calprotectin versus hemoglobin

J. A. Gilbert, D. A. Ahlquist, D. W. Mahoney, A. R. Zinsmeister, J. Rubin, R. D. Ellefson

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

Background: Blood products like hemoglobin are problematic as markers for colorectal neoplasia because bleeding is intermittent. Levels of calprotectin, a leukocyte-derived protein, are increased in stools from colorectal cancer patients. However, this blood constituent may gain luminal access via interstitial leukocyte migration, which could be a less variable mechanism of entry than bleeding. Methods: To correlate the levels of and to compare the variability of fecal calprotectin and hemoglobin, quantitative assays were performed independently on multiple serially collected stools from 14 patients with colorectal cancer. Marker level association was estimated with Pearson's correlation coefficient, and variation estimated with an analysis of variance model. Results: Fecal calprotectin and hemoglobin levels were discordant in 55 (50%) of 110 matched aliquots, and marker levels failed to correlate. The estimated between-subject correlation was -0.10 (95% CI, -0.60 to 0.46), and mean within-subject correlation -0.27 (95% CI, -0.73 to 0.34). The between-stool coefficient of variation was less for calprotectin (22%) than for hemoglobin (80%). Conclusions: In patients with colorectal cancer, the mechanism of luminal calprotectin entry appears to be both different from and less erratic than bleeding.

Original languageEnglish (US)
Pages (from-to)1001-1005
Number of pages5
JournalScandinavian Journal of Gastroenterology
Volume31
Issue number10
StatePublished - 1996

    Fingerprint

Keywords

  • calprotectin
  • colorectal cancer screening
  • HemoQuant
  • occult bleeding
  • stool markers

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Gilbert, J. A., Ahlquist, D. A., Mahoney, D. W., Zinsmeister, A. R., Rubin, J., & Ellefson, R. D. (1996). Fecal marker variability in colorectal cancer: Calprotectin versus hemoglobin. Scandinavian Journal of Gastroenterology, 31(10), 1001-1005.